Opsens – 100,000 cases performed with the OptoWire Quebec City, Quebec, May 20, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) reached an important milestone with more than 100,000 patients evaluated with the OptoWire™, a pressure guidewire for the diagnosis and treatment of coronary artery stenosis. Accuracy in assessing the severity of coronary disease […]
Category: News & Events
The Financial Post: How is OpSens improving cardiovascular disease treatment?
The Financial Post released a piece based on this week’s interview on OpSens’ C-Suite at the Open, a series highlighting the stories of companies listed on the TSX. Link to Financial Post piece […]
OpSens at C-Suite at the Open
TORONTO, April 27, 2020 /CNW/ https://www.youtube.com/watch?v=i7qXYFwhH8g The C-Suite At the Open video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest C-Suite At The Open videos visit http://www.newswire.ca/en/releases/archive/April2020/27/c0533.html. About OpSens Inc. (TSX:OPS) OpSens focuses […]
OPSENS ANNOUNCES Q2 2020 RESULTS
OPSENS ANNOUNCES Q2 2020 RESULTS Quebec City, Quebec, April 9, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter of 2020. Highlights OpSens continues operations and adjusts to face the COVID-19 crisis; Consolidated product sales totaled $8.3 M in the second quarter of 2020 compared with […]
OPSENS PROVIDES OPERATIONAL UPDATE – Continues to supply essential cardiovascular solutions to patients around the world
OPSENS PROVIDES OPERATIONAL UPDATE Continues to supply essential cardiovascular solutions to patients around the world Quebec City, Quebec, March 24, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, today provided a business update in light of recent action taken […]
OPSENS RECEIVES dPR CLEARANCE FROM FDA
Opsens Receives dPR Clearance from the FDA Product approval will bolster U.S. commercial efforts Quebec City, Quebec, December 19, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its diastolic pressure algorithm (“dPR”). Coronary physiology has been in constant evolution with […]
VISIT OPSENS AT SCAI FALL FELLOWS 2019
Learn more about the benefits of OptoWire® as a pressure guidewire to diagnose and treat with confidence at the SCAI Fall Fellows 2019 Annual Meeting by attending Opsens’ complimentary educational symposium. The OptoWire features a large nitinol core with excellent torque response and deliverability. With the OptoWire you can diagnose and treat your patients with confidence. Opsens second […]
OPSENS – RECORD FY2019 CONSOLIDATED REVENUES OF $32.8 M, UP 36%, RECORD FFR REVENUES OF $20 M, UP 41%
OPSENS – RECORD FY2019 CONSOLIDATED REVENUES OF $32.8 M, UP 36%, RECORD FFR REVENUES OF $20 M, UP 41% Quebec City, Quebec, November 14, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for 2019. Highlights FOR THE QUARTER AND FOR THE YEAR Record consolidated revenues at $32.8 M for […]
OPSENS ANNOUNCES ENTRY INTO STRUCTURAL HEART MARKET
OPSENS ANNOUNCES ENTRY INTO STRUCTURAL HEART MARKET Expands core technology into fastest growing segment of cardiology devices Quebec City, Quebec, November 5, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces today it is expanding its medical device business into the structural cardiology space and will accelerate development activities of products that reach […]
